This is a summary of an article describing an ongoing study called MOUNTAINEER. This article was published in The Lancet Oncology in 2023. The study included 117 adults with metastatic HER2-positive colorectal cancer. The researchers wanted to know whether a combination of 2 drugs called tucatinib and trastuzumab could shrink the participants’ cancer. The researchers also wanted to know whether receiving tucatinib alone could also shrink the participants’ cancerThis Plain Language Summary of Publication article from Future Oncology summarises the results from the ongoing study called MOUNTAINEER, researchers wanted to know whether a combination of two drugs called tucatinib and trastuzumab could shrink the participants’ cancer (or if tucatinib alone could shrink the participants’ cancer).

Visit the Future Medicine using the link to read the article.

The original article on which this summary is based is called ‘Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study’ and was published in The Lancet Oncology.

Visit The Lancet using the link to read the original article.